Stocks and Investing Stocks and Investing
Wed, December 20, 2017
Tue, December 19, 2017
Mon, December 18, 2017

Christopher Raymond Initiated (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017


Published on 2024-10-26 01:35:29 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Initiated "Akebia Therapeutics, Inc." (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017.

Christopher has made no other calls on AKBA in the last 4 months.



There are 2 other peers that have a rating on AKBA. Out of the 2 peers that are also analyzing AKBA, 0 agree with Christopher's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Christopher


  • Robert Hazlett of "BTIG" Initiated at Strong Buy and Held Target at $30 on, Thursday, December 7th, 2017
  • Difei Yang of "Mizuho" Initiated at Strong Buy and Held Target at $24 on, Thursday, October 5th, 2017

Contributing Sources